Beta-2-glycoprotein 1

Added to your cart

Beta-2-glycoprotein 1

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P195-5


Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

Beta 2 Glycoprotein 1, sometimes referred to as apolipoprotein H, is a protein of 50 kDa and pI of 5.6-6.4. It is a constituent of chylomicrons, very low density lipoprotein (VLDL) and low density lipoprotein (LDL). B2GP1 is a major phospholipid binding protein. It is an important component which is measured in the assessment of anti-phospholipid syndrome. It is also more specific than anti-cardiolipin antibodies and its presence correlates better with thrombotic risk. This specific example has been protein A treated.

More information



  • Shipping Information
  • Cool Pack
  • Abbreviations
  • B2GP1
  • Specification
  • ≥96%.
  • Recommended Use
  • Research and further manufacturing
  • Storage
  • 2 - 8°C
  • Buffer
  • lyophilised from 0.02M NH4HCO3
  • Presentation Matrix
  • lyophilised from 0.02M NH4HCO3. May contain traces of buffer salts.
  • Purity/grade
  • ≥96%.
  • Source
  • plasma
  • Applications
  • Biosensors, Clinical Chemistry, Control Manufacture, ELISA, Lateral Flow, Life Science
  • Molecular weight
  • 50kDa

Technical Documents

Certificates Of Analysis (164.88KB)

Safety Data Sheet (37.65KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands


The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.


Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.


Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox